The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
Elanco expects Befrena to launch in the US in the first half of 2026
Dr. Chand held several leadership positions within AstraZeneca and the broader biopharmaceutical industry
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
His professional background also includes key experience at Matrix Labs and Sun Pharma
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
Cupid is strengthening its footprint in the GCC region, focusing on supply responsiveness and market proximity
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Subscribe To Our Newsletter & Stay Updated
